Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives Average Recommendation of "Hold" from Brokerages

Key Points

• Supernus Pharmaceuticals has an average “Hold” rating from seven analysts: four buys, two holds, and one sell. The average 12-month price target is $62.83, compared with the stock’s recent price of $42.92.
• Institutional investors increased exposure, including BlackRock’s new $434.9 million position and notable stake increases by Bank of America and Sofinnova Investments.
• In its latest quarter, Supernus reported revenue of $219.1 million, up 32.4% year over year and above estimates, but posted an adjusted loss of $1.01 per share versus expectations for earnings of $0.42.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) has received an average recommendation of "Hold" from the seven research firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $62.8333.

A number of equities research analysts have weighed in on the company. Cantor Fitzgerald lifted their price objective on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an "overweight" rating in a report on Thursday, July 9th. Zacks Research downgraded Supernus Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Friday, September 4th. Wall Street Zen cut Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, August 8th. Finally, Weiss Ratings restated a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new position in shares of Supernus Pharmaceuticals during the 2nd quarter worth $434,871,000. Geode Capital Management LLC lifted its stake in shares of Supernus Pharmaceuticals by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 1,472,899 shares of the specialty pharmaceutical company's stock valued at $73,215,000 after purchasing an additional 62,875 shares during the period. Bank of America Corp DE boosted its holdings in Supernus Pharmaceuticals by 37.2% during the first quarter. Bank of America Corp DE now owns 714,226 shares of the specialty pharmaceutical company's stock worth $36,918,000 after buying an additional 193,479 shares in the last quarter. Ashford Capital Management Inc. boosted its holdings in Supernus Pharmaceuticals by 5.4% during the first quarter. Ashford Capital Management Inc. now owns 645,381 shares of the specialty pharmaceutical company's stock worth $33,360,000 after buying an additional 32,843 shares in the last quarter. Finally, Sofinnova Investments Inc. grew its position in Supernus Pharmaceuticals by 46.7% during the fourth quarter. Sofinnova Investments Inc. now owns 553,095 shares of the specialty pharmaceutical company's stock worth $27,489,000 after buying an additional 176,029 shares during the period.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN opened at $42.92 on Friday. The stock has a market capitalization of $2.50 billion, a P/E ratio of -22.35, a P/E/G ratio of 0.76 and a beta of 0.56. Supernus Pharmaceuticals has a 1 year low of $40.51 and a 1 year high of $59.68. The company's fifty day moving average is $45.63 and its two-hundred day moving average is $47.72.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last issued its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of $0.42 by ($1.43). Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The firm had revenue of $219.06 million during the quarter, compared to analysts' expectations of $205.31 million. During the same period in the previous year, the firm earned $0.40 EPS. The firm's revenue was up 32.4% on a year-over-year basis. Sell-side analysts predict that Supernus Pharmaceuticals will post 1.97 EPS for the current year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) disorders. The company's portfolio addresses conditions including epilepsy, migraine and attention-deficit/hyperactivity disorder (ADHD), with an emphasis on extended-release and other drug-delivery technologies.

Supernus markets Oxtellar XR (oxcarbazepine extended-release) for the treatment of partial-onset seizures and Trokendi XR (topiramate extended-release) for certain epilepsy indications and the prevention of migraine headaches.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.